NutraFuels Takes a Low-Risk Approach in More Than One Way
March 13th, 2017
News, Top News
The market for cannabidiol (CBD) could reach $2.1 billion by 2020, according to The Hemp Business Journal’s CBD Report, growing at 59% compound annual growth rate. With potential regulatory issues facing the recreational cannabis industry, investors may want to take a closer look at companies involved in the CBD-focused medical cannabis and nutraceutical space as a way to capitalize on the industry’s growth without taking on quite as much risk.
At the same time, most nutraceutical companies have taken a very non-scientific approach to developing and marketing their products. In fact, the Food & Drug Administration (FDA) sent a warning letter to companies developing cannabidiol (CBD) oils in 2015 for not presenting any scientific basis for their claims and falsely marketing products that didn’t contain any CBDs. These kind of practices have become commonplace in the industry and make it difficult for consumers to select products.
In this article, we will take a look at NutraFuels Corp.’s (OTC Pink: NTFU) proven, low-risk approach to the cannabis industry, its focus on proving the benefits of its products, and why investors should take note.
The Trump administration has taken a hostile approach to the cannabis industry. In February, White House Press Secretary Sean Spicer suggested that the federal government would step up enforcement of marijuana laws with a focus on recreational marijuana. The move would be a reversal of the Obama administration’s official memo stating that it wouldn’t interfere in states where non-medical (or medical) use of marijuana has been legalized.
Attorney General Jeff Sessions has also been very critical of marijuana legalization, saying that it opens states to ‘violence’ and could face repercussions from the federal government. While Sessions privately reassured legislators that he would not reverse the Justice Department’s existing marijuana policy, there’s little doubt that these attitudes could be subject to change as the Trump administration has become a vocal opponent to the drug.
NutraFuels avoids these concerns through the use of hemp-derived non-psychoactive cannabidiol (CBD), which has demonstrated the potential to treat a variety of medical conditions without the “high” effects associated with tetrahydrocannabinol (THC). In fact, the Drug Enforcement Administration (DEA) has repeatedly tried and failed to regulate hemp in the same way as marijuana with courts ruling that it is not dangerous at all.
NutraFuels is also focused on validating the effectiveness of its products by conducting clinical studies. In February, the company announced that it was preparing clinical trials of its line of oral spray nutraceuticals beginning with its sleep support oral spray that contains CBD. The team plans to begin the studies during the second quarter of 2017 while progressing to studies of its other products over time.
To facilitate the trials, NutraFuels has appointed Kenneth Duchin, Ph.D. as Vice President of Clinical Development. Dr. Duchin has over 30 years in the pharmaceutical industry in various management positions at Bristol-Myers Squibb and in small and mid-size companies (Theravance, IVAX Corporation, Noven Pharmaceuticals) as well as in start-up virtual organizations. He has extensive drug development experience in a broad range of therapeutic areas, has led several registration programs, authored regulatory NDA and ANDA documents and has led cross-functional development teams. In addition, he has been an inventor of 9 patents and has published nearly 40 papers in peer reviewed journals.
Concurrently, the company reached an agreement with Palm Beach Research to conduct the trials. Palm Beach Research has a long history of conducting pharmaceutical trials and easy access to significant patient populations. This type of smart partnership could help NutraFuels avoid common pitfalls of the clinical trial process and smooth out the process for the company.
“We are pleased to announce that we are taking the necessary steps to validate the efficacy and benefit of our products and look forward to producing conclusive data that will demonstrate the quality of the products we produce,” said NutraFuels CEO Edgar Ward.
The Bottom Line
NutraFuels Corp. (OTC Pink: NTFU) has developed a promising line-up of oral spray products designed to address several consumer problems, including sleep, energy, and mood. With its convenience, dose precision, and higher bio-availability, these oral sprays may be more effective than capsules, drinks, and other nutraceutical delivery mechanisms. Investors may want to keep an eye on the stock as it undergoes clinical trials to support its claims.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.